| Prof Richardson’s research regards the discovery of anti-cancer drugs (such as Dp44mT and DpC) for the treatment of belligerent, intractable tumours (e.g., breast, skin, brain, lung, pancreas, prostate, colon, etc). Prof Richardson holds the Alan Mackay-Sim Distinguished Chair of Cancer Cell Biology at Griffith University and is a National Health and Medical Research Council (NHMRC) of Australia Senior Principal Research Fellow. He is also the Director of the Centre for Cancer Cell Biology and Drug Discovery He has published >454 articles, reviews, patents etc and his work over his entire career has been cited >42,000 times (H-Index 100; Google Scholar 14/11/2021). Over the last 5 yrs, he authored 102 articles, reviews, patents, etc.; av ~20 publs./yr: with a 5 year H-index of 62; >21,000 cites over last 5 yrs; Google Scholar 14/11/2021) He is Executive Editor of BBA-General Subjects and has been a member of 48 Ed. Boards, e.g., JBC (2011-2017 & 2017-2022 – Elected 2x), Anti-Oxidants Redox Signaling (2012-), Biochem J (2004-11), Mol Pharmacol (2007-), BBA Mol Cell Res (2014-), BBA- Reviews on Cancer (2019-), Free Rad. Biol. Med. (2020-), Cancers (2020-), etc. As a major translational research achievement, he has developed the anti-cancer and anti-metastatic drug, DpC, which overcomes P-glycoprotein-mediated drug resistance and regulates the potent metastasis suppressor, NDRG1. |
